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SUMMARY
Background
Anti-tumour necrosis factor-alpha agents (anti-TNF) are effective therapies
for the treatment of Crohn’s disease (CD), but their comparative efﬁcacy is
unknown.
Aim
To perform a network meta-analysis comparing the efﬁcacy of anti-TNF
therapies in CD.
Methods
After screening 506 studies, reviewers extracted information on 10 studies.
Traditional meta-analysis (TMA) was used to compare each anti-TNF agent
to placebo. Bayesian network meta-analysis (NMA) was performed to com-
pare the effects of anti-TNF agents to placebo. In addition, sample sizes for
comparative efﬁcacy trials were calculated.
Results
Compared to placebo, TMA revealed that anti-TNF agents result in a higher
likelihood of induction of remission and response (RR: 1.66, 95% CI: 1.17–
2.36 and RR: 1.43, 95% CI: 1.17–1.73, respectively) as well as maintenance of
remission and response (RR: 1.78, 95% CI: 1.51–2.09 and RR: 1.68, 95% CI:
1.46–1.93, respectively). NMA found nonsigniﬁcant trends between inﬂix-
imab and adalimumab or certolizumab pegol. Among subcutaneous thera-
pies, NMA demonstrated superiority of adalimumab to certolizumab pegol
for induction of remission (RR: 2.93, 95% CrI: 1.21–7.75). Sample size calcu-
lations suggest that adequately powered head-to-head comparative efﬁcacy
trials would require greater than 3000 patients.
Conclusions
All anti-TNF agents are effective for induction and maintenance of response
and remission in the treatment of CD. Although adalimumab is superior to
certolizumab pegol for induction of remission, there is no evidence of clinical
superiority among anti-TNF agents. Head-to-head trials among the anti-TNF
agents are impractical in terms of size and cost.
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INTRODUCTION
Anti-tumour necrosis factor alpha (anti-TNF) therapies
are established treatments for moderate to severe Cro-
hn’s disease (CD). Randomised controlled trials of three
anti-TNF agents, inﬂiximab (IFX), adalimumab (ADA),
and certolizumab pegol (CZP), have demonstrated efﬁ-
cacy over placebo and are FDA approved for the induc-
tion and maintenance of clinical response and remission
in moderate to severe CD.1–10 However, while these
anti-TNF agents are each effective against placebo,
whether they share comparable efﬁcacy remains ques-
tioned and has not been well studied.
Biological differences among anti-TNF agents allow
for potential variability in therapeutic properties and efﬁ-
cacy. IFX is a monoclonal IgG1 antibody with a partially
murine anti-TNF Fab region, ADA is an IgG1 antibody
containing a humanised Fab region, and CZP is pegylated
without an Fc region. Despite these molecular differ-
ences, in vitro studies have not demonstrated signiﬁcant
variability in neutralisation of soluble and mem-
brane-bound TNF or modulation of lymphocyte apopto-
sis between these anti-TNF agents.11, 12 Retrospective
and nonrandomised studies have demonstrated IFX and
ADA to have similar clinical outcomes in avoidance of
corticosteroids, surgery, hospitalisation and improvement
in quality of life in patients with CD.13–17 In summary,
biologic and retrospective clinical data suggest similar
therapeutic activity of these agents in CD.
Head-to-head direct comparative efﬁcacy trials among
anti-TNF agents for CD have not been performed. Net-
work meta-analysis (NMA) allows indirect comparisons
of individual anti-TNF agents relative to a common
comparator (placebo), yielding an estimate of compara-
tive efﬁcacy. We performed both traditional and network
meta-analyses of IFX, ADA and CZP clinical trials to
assess comparative efﬁcacy for induction and mainte-
nance among anti-TNF agents for CD.
METHODS
Data sources and search
The study was conducted in accordance with the PRIS-
MA statement.18 PubMed and Embase databases were
the primary sources to identify relevant published, pla-
cebo-controlled, randomised clinical trials of anti-TNF
agents for CD. A search of human studies in these data-
bases from inception through 31 August 2013 was per-
formed using controlled vocabulary descriptors (Medical
Subject Headings and Emtree) and speciﬁc keywords to
represent the concept of CD and therapeutic use of
anti-TNF agents. The studies of interest were pla-
cebo-controlled, randomised studies; retrospective and
observational studies were not included in any of the
analyses.
The search was augmented by manual searches of ref-
erence lists from potentially relevant papers to identify
additional studies that may have been missed using the
computer-assisted strategy. Additionally, all available
guidelines, systematic reviews, and meta-analyses per-
taining to the therapeutic use of anti-TNF agents in CD
were reviewed for any additional potentially relevant
studies. The search was not limited by language, though
a large majority of the manuscripts were originally pub-
lished in English.
Study selection
Two investigators (TL, RS) independently reviewed the
titles of all identiﬁed citations to generate a list of poten-
tially relevant articles for further review. The abstracts of
these articles were reviewed to identify studies suitable for
inclusion in our ﬁnal analyses. For a manuscript to be eli-
gible for our study, it had to satisfy the following eligibility
criteria: (i) studies had to examine the effect of a single
anti-TNF agent on induction and/or maintenance of
response or remission in CD; (ii) the treatment of interest
was anti-TNF agent monotherapy at standard dosing,
although pre-existing concominate therapies were permit-
ted; (iii) studies could not duplicate data already pub-
lished; (iv) studies were published as full manuscripts; (v)
response or remission was deﬁned by a standardised scor-
ing criteria (typically using the Crohn’s Disease Activity
Index – CDAI); (vi) studies were placebo-controlled,
randomised clinical trials with treatment and control
arms. We did not include nonrandomised controlled trials
given the concern for study heterogeneity.
Data extraction
Two authors (TL and RS) independently extracted data
from the included studies via manual review. Discrep-
ancies between data extracted were resolved via consen-
sus. The following data points were extracted for each
study: ﬁrst author; year of publication; number of cen-
tres involved (if multi-centre); drug studied, dosage and
dose interval; blinding and randomisation; clinical end-
points (induction or maintenance of either clinical
response or remission); presence or absence of concom-
itant glucocorticoid or immunosuppressive exposure;
prior anti-TNF agent exposure status; length of fol-
low-up; presence of a drug washout period; numbers of
patients in the treatment and control arms; numbers
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of patients in each arm who achieved induction of
response, induction of remission, maintenance of
response, or maintenance of remission; measurement
of the primary outcome.
Clinical endpoints
We extracted data to evaluate four clinical endpoints: (i)
Induction of Remission – deﬁned as attainment of a CDAI
score of less than 150 within 12 weeks of initiation of
treatment; (ii) Induction of Response – deﬁned as a
decrease in the CDAI score of ≥100 or ≥70 points (based
on aim of study) from the baseline score within 12 weeks
of initiation of treatment; (iii) Maintenance of Remission
– remission (as deﬁned above) maintained at 24–
30 weeks. While some studies included 52 week data,
more complete data were available for 24–30 week time
frames, permitting a more homogenous endpoint
comparison between studies; (iv) Maintenance of
Response – response (as deﬁned above) maintained for
24–30 weeks.
Quality assessment
Two investigators (AD, DS) critically appraised and
quality-rated all eligible studies. The randomised con-
trolled trials were assessed by criteria set forth by the
Evidence-Based Gastroenterology Steering Group (EB-
GSG).19 These criteria were: (i) concealed random alloca-
tion; (ii) blinding of patients and caregivers; (iii) equal
use of co-interventions for the treatment and placebo
groups; (iv) complete follow-up of study patients; and
(v) use of an intention-to-treat analysis. Discrepancies in
quality assessment were resolved by consensus.
Data synthesis and analysis
The outcomes analysed included induction and mainte-
nance of clinical response or remission in CD. Traditional
486 citations identified using Medline, Embase,
PubMed, and 20 citations from manual review
of previously published systematic analyses
(506 total)
376 potentially relevant citations identified
17 studies selected for manual review and
eligibility
10 studies eligible and included in the analysis
6 studies evaluated anti-TNF agents for induction therapy 5 studies evaluated anti-TNF agents for maintenance therapy
7 Manuscripts excluded on final screening
-1 used dosing not used in clinical practice
-1 included pediatric patients
-3 did not contain an anti-TNF agent alone as the
treatment
-2 used a nonstandard efficacy endpoint (ie: not CDAI)
130 citations excluded for being review articles
359 citations excluded after secondary screening
-90 were not relevant
-118 were redundant
-92 were guidelines or commentaries
-12 were test performance studies
-39 were relevent but were not RCTs
-8 were pediatric studies
6 studies included in the network meta-analysis
for induction of clinical remission in CD
6 studies included in the network meta-analysis
for induction of clinical response in CD
4 studies included in the network meta-analysis
for maintenance of clinical remission in CD
5 studies included in the network meta-analysis
for maintenance of clinical remission in CD
Figure 1 | Study inclusion protocol for induction and maintenance of clinical response and remission in Crohn’s
disease.
Aliment Pharmacol Ther 2014; 39: 1349-1362 1351
ª 2014 John Wiley & Sons Ltd
Systematic review with network meta-analysis: anti-TNF therapies for Crohn’s disease
Table 1 | Characteristics of the included studies for the use of anti-TNF agents in the treatment of Crohn’s disease
Study Drug Dosage Interval
Baseline meds
allowed
Immunosuppressant
use (Ctrl%/Tx%)
Prev
anti-TNF:
Ctrl/Tx/
Washout
Quality
score
Induction of clinical remission in Crohn’s disease
Hanaeur et al.
20064
(CLASSIC-I)
Adalimumab 160 mg,
80 mg SC
Weeks 0
and 2
5-ASA, CCS, AZA,
MCP, MTX, ABX
AZA: 18%/14%
MCP: 11%/13%
MTX: 1%/1%
CCS: 34%/32%
Not allowed 5
Sandborn et al.
20077 (GAIN)
Adalimumab 160 mg,
80 mg SC
Weeks 0
and 2
5-ASA, CCS, AZA,
MCP, MTX, ABX
Any IS†: 51%/46%
CCS: 44%/35%
100%/100%/
2 month
washout
5
Sandborn et al.
20075
(PRECISE-I)
Certolizumab
Pegol
400 mg SC Weeks 0,
2 and 4
5-ASA, CCS, AZA,
MCP, MTX, ABX
Any IS: 20%/21%
CCS: 40%/39%
26%/30%/
3 month
washout
5
Sandborn
et al. 201110
Certolizumab
Pegol
400 mg SC Weeks 0,
2 and 4
5-ASA, CCS,
Immunosup-
presants*, ProBX
Any IS: 31%/35%
CCS: 46%/44%
Not allowed 5
Schreiber
et al. 20053
Certolizumab
Pegol
400 mg SC Weeks 0,
4 and 8
5-ASA, CCS, AZA,
MCP, MTX
AZA: 23%/31%
MCP: 6%/3%
MTX: 7%/4%
CCS: 40%/31%
22%/12%/
3 month
washout
4
Targan
et al. 19971
Inﬂiximab 5 mg/kg IV Week 0 5-ASA, CCS, AZA,
MCP
AZA: 28%/19%
MCP: 16%/15%
CCS: 64%/56%
anti-TNF
agents
unavailable
4
Induction of clinical response in Crohn’s disease
Hanaeur
et al. 20064
(CLASSIC-I)
Adalimumab 160 mg,
80 mg SC
Weeks 0
and 2
5-ASA, CCS, AZA,
MCP, MTX, ABX
AZA: 18%/14%
MCP: 11%/13%
MTX: 1%/1%
CCS: 34%/32%
Not allowed 5
Sandborn
et al. 20077
(GAIN)
Adalimumab 160 mg,
80 mg SC
Weeks 0
and 2
5-ASA, CCS, AZA,
MCP, MTX, ABX
Any IS†: 51%/46%
CCS: 44%/35%
100%/100%/
2 month
washout
5
Sandborn
et al. 20075
(PRECISE-I)
Certolizumab
Pegol
400 mg SC Weeks 0,
2 and 4
5-ASA, CCS, AZA,
MCP, MTX, ABX
Any IS: 20%/21%
CCS: 40%/39%
26%/30%/
3 month
washout
5
Sandborn
et al. 201110
Certolizumab
Pegol
400 mg SC Weeks 0,
2 and 4
5-ASA, CCS,
Immunosup-
presants*, ProBX
Any IS: 31%/35%
CCS: 46%/44%
Not allowed 5
Schreiber
et al. 20053
Certolizumab
Pegol
400 mg SC Weeks 0,
4 and 8
5-ASA, CCS, AZA,
MCP, MTX
AZA: 23%/31%
MCP: 6%/3%
MTX: 7%/4%
CCS: 40%/31%
22%/12%/
3 month
washout
4
Targan
et al. 19971
Inﬂiximab 5 mg/kg IV Week 0 5-ASA, CCS, AZA,
MCP
AZA: 28%/19%
MCP: 16%/15%
CCS: 64%/56%
anti-TNF
agents
unavailable
4
Maintenance of Clinical Remission in Crohn’s Disease
Colombel et al.
20079
(CHARM)
Adalimumab 40 mg SC Every
2 weeks
5-ASA. CCS, AZA,
MCP, MTX, ABX
Any IS: 77.1%/79.1% 47.6%/49.3%/
3 month
washout
5
Sandborn et al.
20076
(CLASSIC-II)
Adalimumab 40 mg SC Every
2 weeks
5-ASA, CCS, AZA,
MCP, MTX, ABX
AZA: 6%/21%
MCP: 6%/0%
MTX: 6%/0%
CCS: 56%/47%
Not allowed 5
Sandborn et al.
20075
(PRECISE-I)
Certolizumab
Pegol
400 mg SC Every
4 weeks
5-ASA, CCS, AZA,
MCP, MTX, ABX
Any IS: 20%/21%
CCS: 40%/39%
26%/30%/
3 month
washout
5
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meta-analysis was used for the direct pairwise compari-
sons of each anti-TNF vs. placebo and was performed
using random-effects meta-analysis techniques in Stata
13.1 (StataCorp, College Station, TX, USA). The differ-
ences between random effects and ﬁxed effects were also
evaluated when only a single study for a particular drug
was evaluated. The Cochran Q-test and I2 inconsistency
statistic were used to assess for statistical heterogeneity
between trials. When heterogeneity was present,
meta-inﬂuence analysis and Galbraith plot assessment
were performed to identify responsible outlier studies.
Pooled relative risks (RRs) and their 95% conﬁdence
intervals (95% CIs) were estimated for the various
anti-TNF agents.
To compare the efﬁcacy of the anti-TNF agents, a
Bayesian network meta-analysis (NMA) was performed
with the GeMTC GUI statistical package.20 This form of
meta-analysis allows for the analysis of both direct and
indirect comparisons and generates estimates of effect
(with 95% credible intervals) for all possible pairwise
comparisons despite not being evaluated directly in a
head-to-head fashion in the included clinical trials. The
technique of NMA, in this situation, allows for the for-
mation of indirect comparisons between anti-TNF agents
using placebo as a common comparator. In addition, the
analysis allows for the ranking of different interventions
in order to evaluate the comparative efﬁcacy. For each
individual analysis, simulations were repeated 50 000
times to allow convergence and an additional 50 000
simulations were performed to produce the probability
statements. Convergence of iterations was evaluated
using Gelman-Rubin-Brooke statistic. For this analysis,
Markov chain Monte Carlo simulations were utilised to
estimate posterior distributions. As direct head-to-head
Table 1 | (Continued)
Study Drug Dosage Interval
Baseline meds
allowed
Immunosuppressant
use (Ctrl%/Tx%)
Prev
anti-TNF:
Ctrl/Tx/
Washout
Quality
score
Schreiber et al.
20078
(PRECISE-II)
Certolizumab
Pegol
400 mg SC Every
4 weeks
5-ASA, CCS, AZA,
MCP, MTX, ABX
Any IS: 41%/40%
CCS: 37%/35%
24%/24%/
3 month
washout
5
Hanauer
et al. 20022
(ACCENT-I)
Inﬂiximab 5 mg/kg IV Every
8 weeks
5-ASA, CCS, AZA,
MCP, MTX, ABX
Immunosuppressant
use data not
available
Not allowed 5
Maintenance of clinical response in Crohn’s disease
Colombel et al.
20079
(CHARM)
Adalimumab 40 mg Every
2 weeks
5-ASA. CCS, AZA,
MCP, MTX, ABX
Any IS: 77.1%/79.1% 47.6%/49.3%/
3 month
washout
5
Sandborn et al.
20076
(CLASSIC-II)
Adalimumab 40 mg Every
2 weeks
5-ASA, CCS, AZA,
MCP, MTX, ABX
AZA: 6%/21%
MCP: 6%/0%
MTX: 6%/0%
CCS: 56%/47%
Not allowed 5
Sandborn
et al. 20075
(PRECISE-I)
Certolizumab
Pegol
400 mg Every
4 weeks
5-ASA, CCS, AZA,
MCP, MTX, ABX
Any IS: 20%/21%
CCS: 40%/39%
26%/30%/
3 month
washout
5
Schreiber
et al. 20078
(PRECISE-II)
Certolizumab
Pegol
400 mg Every
4 weeks
5-ASA, CCS, AZA,
MCP, MTX, ABX
Any IS: 41%/40%
CCS: 37%/35%
24%/24%/
3 month
washout
5
CCS, corticosteroids; 5-ASA, 5-aminosalicylates; MCP, mercaptopurine; AZA, azathioprine; MTX, methotrexate; ABX, antibiotics;
ProBX, probiotics.
Clinical remission by CDAI (Crohn’s Disease Activity Index) deﬁned as score <150 points. Clinical response by CDAI (Crohn’s
disease activity index) deﬁned as a reduction of ≥100 points, except in Targan et al. 1997, where response was deﬁned by a
decrease ≥70 points. Washout in all cases refers to absence period free of anti-TNF agents if previous receipt of Anti-TNF agents
was allowed. Acronyms of studies are provided in parentheses, if available.
* In Sandborn et al. 2011, immunosuppressants were allowed concomitant to the study. However, speciﬁc drugs were not further
speciﬁed.
† Any IS signiﬁes concurrent use of any of the immunosuppressants: methotrexate, mercaptopurine or aziothioprine (this cate-
gory excludes 5-Aminosalicylates and glucocorticoids).
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comparative data are lacking, we conservatively chose to
use a non-informative uniform prior distribution of
effect sizes and precision in this NMA.
Sensitivity analyses and sample size estimates
To assess the robustness of the results, separate tradi-
tional meta-analyses were repeated after eliminating sta-
tistical heterogeneity by removing outlier studies if any,
and excluding studies that did not require response
before randomisation into the maintenance study. In
instances where nonstandard induction regimens were
used in maintenance studies, a sensitivity analysis was
performed. Based on the results of this NMA, sample
sizes for between-drug comparative effectiveness studies
were calculated with the sampsi command in Stata 13.1,
assuming 80% power and a 2-sided alpha of 0.05.
RESULTS
Literature search
A ﬂow diagram depicting the search and selection process
is provided in Figure 1. Initial searches of the Medline
and Embase databases yielded 486 citations. Manual
search of the PubMed database for pertinent systematic
reviews, meta-analyses, and guidelines identiﬁed 4 sum-
mary documents, a review of which yielded 20 additional
citations for a total of 506 citations. Title review of these
two groups of citations yielded 376 unique potentially rel-
evant articles. Abstract and/or brief manuscript review of
these articles yielded 17 manuscripts appropriate for
detailed evaluation. Ten of the remaining manuscripts
were included in the ﬁnal analysis. There was 100% agree-
ment between reviewers regarding ﬁnal study selection.
Characteristics of included studies
Characteristics of the included studies are listed in
Table 1. The 10 studies meeting eligibility criteria
included a total of 1771 subjects for induction and 1690
subjects for maintenance. No comparative effectiveness
studies were identiﬁed; all included studies compared pla-
cebo to various anti-TNF therapies in CD. Two studies
compared IFX to placebo. Among these, one study evalu-
ated remission and response as endpoints for induction
(n = 52), and the other study evaluated only remission as
an endpoint for maintenance (n = 223).1, 2 Four studies
compared ADA to placebo, of which two evaluated
remission and response as an endpoint for induction
(n = 475) and two evaluated remission and response as
an endpoint for maintenance (n = 379).4, 6, 7, 9 Four
studies compared CZP to placebo, of which three evalu-
ated remission and response as an endpoint for induction
(n = 1244) and two evaluated remission and response as
an endpoint for maintenance (n = 1088).3, 5, 8, 10 Results
of the selected trials are summarised in Table 2.
Testing for heterogeneity between eligible studies
Pooled analysis of the effects of IFX, ADA and CZP on
induction (remission and response) and maintenance
(remission and response) demonstrated no signiﬁcant
statistical heterogeneity among anti-TNF agents.
Meta-analysis results
Induction of remission or response. Compared to pla-
cebo, traditional meta-analysis revealed that anti-TNF
agents result in a 1.66-fold higher likelihood of induction
of remission (95% CI: 1.17–2.36) and 1.43-fold higher
likelihood of induction of response (95% CI: 1.17–1.73)
compared to placebo. IFX resulted in a 3.70-fold higher
likelihood of inducing remission (95% CI: 0.87–15.80)
and 4-fold higher likelihood of inducing response (95%
CI: 1.29–12.44) compared to placebo. ADA resulted in a
2.94-fold higher likelihood of inducing remission (95%
CI: 1.86–4.66) and 1.71-fold higher likelihood of induc-
ing response (95% CI: 1.31–2.24) compared to placebo.
CZP resulted in a 1.22-fold higher likelihood of inducing
remission (95% CI: 1.00–1.50) and 1.25-fold higher like-
lihood of inducing response (95% CI: 1.07–1.46) com-
pared to placebo. (Figure 2a,b).
Network meta-analysis of agents for induction of
remission demonstrated trends of IFX being superior to
ADA (RR: 1.52 for IFX vs. ADA, 95% CrI: 0.20–17.46)
and CZP (RR: 4.29 for IFX vs. CZP, 95% CrI:
0.65–46.09), but these results did not reach statistical sig-
niﬁcance. Between subcutaneous anti-TNF agents, it is
notable that ADA was superior to CZP in the induction
of remission (RR: 2.93 for ADA vs. CZP, 95% CrI: 1.21–
7.75). Rank order analysis demonstrated that IFX was
the most effective in 66.7% of simulations, ADA was
most effective in 33.3% of simulations and CZP was not
most effective in any simulations.
The network meta-analysis of agents for the induction
of response suggested IFX was superior to both ADA and
CZP, however these trends did not reach statistical signif-
icance (RR: 3.17 for IFX vs. ADA, 95% CrI: 0.53–22.96;
RR: 5.36 for IFX vs. CZP, 95% CrI: 0.91–40.15). Among
subcutaneous anti-TNF treatments for induction of
response, neither was shown to be signiﬁcantly superior
(RR: 1.73 for ADA vs. CZP, 95% CrI: 0.69–4.25). IFX was
ranked the most effective drug in 87% of the simulations,
while ADA was favoured in 12% and CZP in 1%.
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Table 2 | Efﬁcacy data of the included studies for the use of anti-TNF agents in Crohn’s disease
Study Drug Endpoint Study design
Follow-up
(weeks)
Results
Control (%) Anti-TNF (%)
Induction of clinical remission in Crohn’s disease
Hanaeur et al.
20064 (CLASSIC-I)
Adalimumab Remission (CDAI) All subjects included 4 9/74 (12.2) 27/76 (35.5)
Sandborn et al.
20077 (GAIN)
Adalimumab Remission (CDAI) All subjects included 4 12/166 (7.2) 34/159 (21.4)
Sandborn et al.
20075 (PRECISE-I)
Certolizumab
Pegol
Remission (CDAI) All subjects included 6 57/329 (17.3) 71/331 (21.4)
Sandborn et al.
201110
Certolizumab
Pegol
Remission (CDAI) All subjects included 6 53/215 (24.6) 68/223 (30.5)
Schreiber et al. 20053 Certolizumab
Pegol
Remission (CDAI) All subjects included 12 17/73 (23.3) 19/73 (26.0)
Targan et al. 19971 Inﬂiximab Remission (CDAI) All subjects included 12 2/25 (8.0) 8/27 (29.6)
Induction of clinical response in Crohn’s disease
Hanaeur et al.
20064 (CLASSIC-I)
Adalimumab Response (CDAI
Decrease by 100)
All subjects included 4 18/74 (24.3) 38/76 (50.0)
Sandborn et al.
20077 (GAIN)
Adalimumab Response (CDAI
Decrease by 100)
All subjects included 4 41/166 (24.7) 61/159 (38.4)
Sandborn et al.
20075 (PRECISE-I)
Certolizumab
Pegol
Response (CDAI
Decrease by 100)
All subjects included 6 87/329 (26.4) 115/331 (34.7)
Sandborn et al. 201110 Certolizumab
Pegol
Response (CDAI
Decrease by 100)
All subjects included 6 71/215 (33.0) 87/223 (39.0)
Schreiber et al. 20053 Certolizumab
Pegol
Combined endpoint:
response (CDAI
decrease by 100) +
remission (CDAI)*
All subjects included 12 26/73 (35.5) 32/73 (43.8)
Targan et al. 19971 Inﬂiximab Response (CDAI
Decrease by 70)
All subjects included 12 3/25 (12.0) 13/27 (48.1)
Maintenance of clinical remission in Crohn’s disease
Colombel et al.
20079 (CHARM)
Adalimumab Remission (CDAI) Responders only 26 29/170 (17.1) 68/172 (39.5)
Sandborn et al.
20076 (CLASSIC-II)
Adalimumab Remission (CDAI) Responders only 24 9/18 (50.0) 16/19 (84.2)
Sandborn et al.
20075 (PRECISE-I)
Certolizumab
Pegol
Remission (CDAI) All subjects included 26 32/329 (9.7) 47/331 (14.2)
Schreiber et al.
20078 (PRECISE-II)
Certolizumab
Pegol
Remission (CDAI) Responders only 26 60/212 (28.3) 103/216 (47.7)
Hanauer et al.
20022 (ACCENT-I)
Inﬂiximab Remission (CDAI) Responders only 30 23/110 (20.9) 44/113 (38.9)
Maintenance of clinical response in Crohn’s disease
Colombel et al.
20079 (CHARM)
Adalimumab Response (CDAI) Responders only 26 45/170 (26.5) 89/172 (51.7)
Sandborn et al.
20076 (CLASSIC-II)
Adalimumab Response (CDAI) Responders only 24 11/18 (61.1) 16/19 (84.2)
Sandborn et al.
20075 (PRECISE-I)
Certolizumab
Pegol
Response (CDAI) All subjects included 26 52/329 (15.8) 75/331 (22.7)
Schreiber et al.
20078 (PRECISE-II)
Certolizumab
Pegol
Response (CDAI) Responders only 26 76/212 (35.8) 135/216 (62.5)
Clinical remission by CDAI (Crohn’s disease activity index) deﬁned as score <150 points. Clinical response by CDAI deﬁned as a
reduction of ≥100 points, except in Targan et al. 1997, where response was deﬁned by a decrease ≥70 points. For the study
design column, ‘All subjects included’ means that the outcome of interest was measured among all trial participants. For the
study design column, ‘Responders only’ means that the outcome of interest was measured only among those found to have had
a positive response by CDAI score (reduction in CDAI by 70 points) within 4 weeks (people who did not achieve this,
nonresponders, were not analysed in the outcome of interest). Acronyms of studies are provided in parentheses if available.
* In Schreiber et al. 2005, this result was a combined endpoint of clinical response and clinical remission (response and remis-
sion deﬁned as above).
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Infliximab
Study
ID RR (95% Cl)
Events,
Anti-TNF Placebo Weight
Events, %
Targan (1997)
Subtotal (I 2 = .%, P = .)
Adalimumab
Hanaeur (2006)
Sandborn (2007)
Cetrolizumab Pegol
Sandborn (2007)
Sandborn (2011)
NOTE: Weights are from random effects analysis
Overall
(χ2 = 0.13.69,df = 5, I2 = 63.5%, P = 0.018)
Schreiber (2005)
Subtotal
(χ2 = 0, df = 1, I 2 = 0.0%, P = 0.979)
Subtotal
(χ2 = 0.11, df = 2, I2 = 0.0%, P = 0.948)
3.70 (0.87, 15.80)
2.92 (1.48, 5.78)
2.96 (1.59, 5.51)
2.94 (1.86, 4.66)
1.12 (0.63, 1.97)
1.24 (0.90, 1.69)
1.24 (0.91, 1.68)
1.22 (1.00, 1.50)
1.66 (1.17, 2.36)
3.70 (0.87, 15.80)
0.0633 1 15.8
8/27 2/25 100.00
100.00
45.26
54.74
100.00
12.94
42.55
44.51
100.00
2/25
9/74
12/166
21/240
17/73
57/329
53/215
127/617
150/882
8/27
27/76
34/159
61/235
19/73
71/331
68/223
158/627
227/889
(a)
Infliximab
Study
ID RR (95% Cl)
Events,
Anti-TNF Placebo Weight
Events, %
Targan (1997)
Subtotal (I 2 = .%, P = .)
Adalimumab
Hanaeur (2006)
Sandborn (2007)
Certolizumab Pegol
Sandborn (2007)
Sandborn (2011)
NOTE: Weights are from random effects analysis
Overall
(χ2 = 8.78, df = 5, I 2 = 43.0%, P = 0.118)
Schreiber (2005)
Subtotal
(χ2 = 0.94, df = 1, I 2 = 0.0%, P = 0.333)
Subtotal
(χ2 = 0.38, df = 2, I 2 = 0.0%, P = 0.829)
4.01 (1.29, 12.44)
2.06 (1.30, 3.26)
1.55 (1.12, 2.16)
1.71 (1.31, 2.24)
1.23 (0.82, 1.84)
1.31 (1.04, 1.66)
1.18 (0.92, 1.52)
1.25 (1.07, 1.46)
1.43 (1.17, 1.73)
4.01 (1.29, 12.44)
0.0804 1 12.4
13/27 3/25 100.00
100.00
34.03
65.97
100.00
15.22
45.60
39.18
100.00
3/25
18/74
41/166
59/240
26/73
87/329
71/215
184/617
246/882
13/27
38/76
61/159
99/235
32/73
115/331
87/223
234/627
346/889
(b)
Figure 2 | Panel: Meta-analysis of anti-TNFs for the treatment of Crohn's disease. (a) Meta-analysis of the induction
of remission endpoint. (b) Meta-analysis of the induction of response endpoint. (c) Meta-analysis of the maintenance
of remission endpoint. (d) Meta-analysis of the maintenance of response endpoint.
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Infliximab
Study
ID RR (95% Cl)
Events,
Anti-TNF Placebo Weight
Events, %
Hanauer (2002)
Subtotal (I 2 = .%, P = .)
Adalimumab
Sandborn (2007)
Colombel (2007)
Certolizumab Pegol
Sandborn (2007)
NOTE: Weights are from random effects analysis
Overall (I 2 = 0.0%, P = 0.562)
Schreiber (2007)
Subtotal
(χ2 = 1.09, df = 1, I 2 = 8.1%, P = 0.297)
Subtotal
(χ2 = 0.33, df = 1, I 2 = 0.0%, P = 0.566)
1.68 (1.02, 2.78)
2.32 (1.59, 3.39)
2.06 (1.50, 2.82)
1.68 (1.30, 2.18)
1.46 (0.96, 2.23)
1.62 (1.30, 2.02)
1.78 (1.51, 2.09)
1.86 (1.21, 2.86)
0.295 1 3.39
100.00
37.53
62.47
100.00
73.18
26.82
100.00
23/110
9/18
29/170
38/188
60/212
32/329
92/541
153/839
44/113
1.86 (1.21, 2.86) 100.0023/11044/113
16/19
68/172
84/191
103/216
47/331
150/547
278/851
(c)
Study
ID RR (95% Cl)
Events,
Anti-TNF Placebo Weight
Events, %
Adalimumab
Sandborn (2007)
Colombel (2007)
Certolizumab Pegol
Sandborn (2007)
NOTE: Weights are from random effects analysis
Overall (I 2 = 0.0%, P = 0.392)
Schreiber (2007)
Subtotal
(χ2 = 2.02, df = 1, I 2 = 50.4%, P = 0.156)
Subtotal
(χ2 = 1.05, df = 1, I 2 = 4.7%, P = 0.306)
1.74 (1.42, 2.15)
1.64 (1.37, 1.97)
1.68 (1.46, 1.93)
0.383 1 2.61
69.31
100.00
76/212
128/541
184/729
1.38 (0.91, 2.09) 41.3111/1816/19
1.95 (1.46, 2.61) 58.6945/17089/172
135/216
1.69 (1.19, 2.41) 100.0056/188105/191
210/547
1.43 (1.04, 1.97) 30.6952/32975/331
315/738
(d)
Figure 2 | (Continued).
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Maintenance of remission or response. Compared to
placebo, traditional meta-analysis revealed that anti-TNF
agents result in a 1.78-fold higher likelihood of mainte-
nance of remission (95% CI: 1.51–2.09) and 1.68-fold
higher likelihood of maintenance of response (95% CI:
1.46–1.93) compared to placebo. IFX resulted in a
1.86-fold higher likelihood of maintaining remission
compared to placebo (95% CI: 1.21–2.86). ADA resulted
in a 2.06-fold higher likelihood of maintaining remission
(95% CI: 1.50–2.82) and 1.69-fold higher likelihood of
maintaining response (95% CI: 1.19–2.41) compared to
placebo. CZP resulted in a 1.62-fold higher likelihood of
maintaining remission (95% CI: 1.30–2.02) and 1.64-fold
higher likelihood of maintaining response (95% CI: 1.37–
1.97) compared to placebo (Figure 2c,d).
Network meta-analysis of agents for maintenance of
remission did not show signiﬁcant difference between
agents (ADA vs. IFX RR: 1.42, 95% CrI: 0.17–9.27; IFX
vs. CZP RR: 1.23, 95% CrI: 0.26–13.14; ADA vs. CZP
RR: 1.81, 95% CrI: 0.55–8.51). ADA was ranked the
most effective drug in 63% of simulations, IFX in 29%
and CZP in 7%.
Finally, the network meta-analysis of agents for the
maintenance of response demonstrated no statistically
signiﬁcant difference between agents ADA vs. CZP (RR:
1.45, 95% CrI: 0.36–6.08); compatible IFX data were not
available. ADA was ranked the most effective drug in
75% of simulations and CZP ranked ﬁrst in 25% of sim-
ulations.
Direct comparison sample size estimations
Using data generated by our NMA as a measure of effect
size, the required sample sizes for direct comparative
effectiveness trials between anti-TNF agents are large,
requiring over 3000 subjects (Table 3).
Publication bias
The funnel plot asymmetry test for publication bias using
the Harbord test was negative for induction of remission
(P = 0.12, n = 6), maintenance of remission (P = 0.96,
n = 5), and maintenance of response (P = 0.34, n = 4).
However, asymmetry testing approached signiﬁcance for
induction of response (P = 0.053, n = 6), likely due to the
small enrolment in the Targan et al. study resulting in an
inﬂated treatment effect.1
Sensitivity analysis
The sensitivity analyses using traditional meta-analyses
did not substantively change the results. Speciﬁcally,
excluding studies that did not require response before
randomisation into the maintenance study (n = 1, Sand-
born et al. 20075), and maintenance studies that used
nonstandard induction regimens (n = 1, Colombel et al.
20079).
DISCUSSION
Comparative efﬁcacy of anti-TNF therapies for Crohn’s
disease remains a commonly debated topic with great
implications for treatment algorithms when considering
which anti-TNF to utilise ﬁrst for an individual patient.
Further, the near-term entry of several new biological
and small molecule therapies for CD will raise questions
of how to optimally sequence the variety of new thera-
peutic mechanisms in CD. Traditional analysis of com-
parable anti-TNF clinical trials presented here reinforces
the efﬁcacy of this medication class, echoing the results
of prior meta-analyses.21, 22 To our knowledge, this
study is the ﬁrst to assess comparative efﬁcacy of
anti-TNF agents in CD through a network meta-analysis.
Using non-informative priors for conservative results, no
individual anti-TNF agent was shown to be statistically
superior for remission or maintenance of CD by CDAI.
Rank order analysis showed higher remission and
response rates for induction using IFX, while ADA was
favoured for maintenance of remission therapy, although
the 95% credibility interval crossed 1. These ﬁndings
suggest potential variable efﬁcacy, yet sample sizes
required to detect such differences as part of a head-to--
head trial are impractically large.
Several open-label studies have evaluated comparative
efﬁcacy of anti-TNF therapies in Crohn’s disease. Single
centre nonrandomised open-label cohort studies have
shown comparable efﬁcacy and safety between IFX and
ADA at 1 year.23 Yet, issues of small study size, the
absence of randomisation, and the lack of objective
assessments of disease activity preclude ﬁrm conclusions
on comparative efﬁcacy from these data. Further, one
Table 3 | Total number of subjects required for
comparative efﬁcacy RCTs between anti-TNF agents for
CD induction and maintenance of remission
Total subject
number
(induction/
maintenance) Inﬂiximab
Certolizumab
pegol Adalimumab
Inﬂiximab – 3272/558 4780/3076
Certolizumab
pegol
3272/558 – 104518/286
Adalimumab 4780/3076 104518/286 –
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would expect that if anti-TNF agents have no signiﬁ-
cant difference in efﬁcacy that they should be inter-
changeable. In-class anti-TNF switching following
secondary loss of response due to anti-drug antibody
formation has been shown to re-establish disease con-
trol, but this point does not necessarily support true
inter-changeability of anti-TNF therapies.24 Van Assche
and colleagues investigated the impact of elective
switching of anti-TNF agents in a randomised open-
label trial substituting IFX with ADA in subjects with
clinically controlled CD.25 A signiﬁcant portion of
patients returned to IFX after 1 year due to dis-
ease-related complications while on ADA, despite allow-
ing for dose escalation and optimisation in both groups
and observing stable anti-TNF drug levels. While the
SWITCH study was not designed with the intent of
determining comparative efﬁcacy between IFX and
ADA, these data raise doubts that anti-TNF therapies
are completely equivalent in CD.
Absent clear evidence of an individual anti-TNF dem-
onstrating superior efﬁcacy in CD, safety, cost and patient
preference considerations impact the initial choice of
anti-TNF. Safety is believed comparable between anti-
TNFs, comprehensively evaluated in recent meta-analyses
of various adverse effects such as the risk of melanoma,26
opportunistic infections27 and lymphoma.28 Some data
suggest IFX may have higher rates of attenuation of
response and intolerance.29 While prospective registry
studies of maternal–foetal outcomes following exposure to
anti-TNF continue to collect data, CZP has been shown to
have lower placental transfer, which subsequently could
confer a safety advantage for women planning pregnan-
cies; a considerable consideration given the demographic
of young, fertile women with CD.30
Anti-TNF therapies have been shown to reduce the
overall economic burden of Crohn’s disease, offsetting
their high cost over time.31, 32 However, infusion-related
costs are frequently cited as economic reasons to con-
sider subcutaneous therapy. Retrospective studies in the
United States and United Kingdom have suggested that
switching from IFX to ADA could result in an annual
cost savings of US$7000 without increasing dis-
ease-related expenditures in hospitalisation, surgery, or
diagnostics, even when allowing for nonsystematic ADA
dose escalation.33, 34 Subcutaneous anti-TNF may have
an economic advantage over infused agents, though
more detailed studies of the ﬁnancial impact of dose
escalation are needed. Finally, patient surveys in both
IBD and rheumatoid arthritis repeatedly report that after
side effect proﬁle, route of administration is the next
most important factor with patients preferring subcuta-
neous over infusion based anti-TNF therapies.35, 36
The limitations of current clinical trial endpoints, as
well as those of NMA, must be considered when interpret-
ing the presented results. The utility of CDAI as a measure
of disease activity has been increasingly questioned. Short-
comings of CDAI include its lack of concordance with
objective measures of disease activity, poor prediction of
prolonged remission, and limited reproducibility.37, 38
Further, phenotypic heterogeneity of CD, including
inﬂammatory and ﬁbrostenotic features, is not well char-
acterised by CDAI. These limitations prevent accurate
assessment of the inﬂammatory burden of disease activity,
which is most amenable to the therapies being evaluated.
Objective endpoints of mucosal inﬂammation represent a
more reproducible and prognostic measure of therapeutic
efﬁcacy in IBD. Endoscopic scoring in conjunction with
complementary biomarkers and incorporation of patient-
reported outcomes (PRO) instruments are increasing
being utilised to comprehensively assess therapeutic efﬁ-
cacy and represent the future of disease activity assess-
ment.39, 40 C-reactive protein (CRP) measurements were
reported in a portion of the included trials, however nei-
ther data collection nor stratiﬁcation by CRP was uniform
across the included studies. Regardless of methodological
rigour, CDAI is neither sufﬁciently accurate nor reproduc-
ible as a measure of disease activity and is a signiﬁcant
limitation to any comparative analysis in CD.
Despite reﬁning the list of included studies in this
NMA to randomised placebo-controlled trials with con-
ventional anti-TNF dosing using a common shared end-
point, variations in study protocol may have impacted
the results. Studies did not stratify by disease phenotype
or ﬁstula activity; thought one study (Sandborn et al.
201110) excluded patients with active perianal disease.
Studies were not uniform in the explicit exclusion of
patients with known or suspected obstructive ﬁbrostenot-
ic strictures. Further, induction regimens were not uni-
form and varied from current standards, limiting
applicability of the results. CHARM (ADA) used an
80 mg/40 mg induction regimen.9 ACCENT-I (IFX)
completed standard induction of 5 mg/kg at 0, 2 and
6 weeks, but the decision to continue into the mainte-
nance phase was made based on clinical response at
week 2 after a single 5 mg/kg infusion.2 CLASSIC-II
(ADA) required clinical remission for randomisation into
the maintenance study, potentially selecting for subjects
with a more robust clinical response to anti-TNF.6 How-
ever, a sensitivity analysis excluding CLASSIC-II data did
not meaningfully change the results. Prior anti-TNF
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exposure also varied between trials. Subjects in all
selected IFX studies and CLASSIC-I/II (ADA) studies
were anti-TNF na€ıve. Of those in the PRECISE-I/II CZP
studies, approximately 28% of subjects were previously
exposed to an anti-TNF, while in the CHARM (ADA)
maintenance study 49.6% had prior anti-TNF exposure.
Finally, one ADA study required prior IFX use as inclu-
sion criteria.7 While there is no clear bias presented by
the selected studies, standardisation or stratiﬁcation of
prior anti-TNF exposure status may have made the indi-
rect comparison more accurate.
Finally, there are several technical aspects that must
be considered when using NMA. Without direct compar-
ative data to inform the network, we chose to use
non-informative priors for treatment effects and assumed
homogeneous variance between studies. This unbiased
approach is commonly used in NMA and is considered
the most conservative for indirect comparison, but it is
subject to increased type-II error. Thorlund and col-
leagues have used informative priors to estimate variance
and improve precision of the analysis.41 Our group
recently published a comparative effectiveness study for
anti-TNF agents in ulcerative colitis showing a trend of
IFX superiority over ADA for induction (RR = 0.46,
95% CrI: 0.10–3.05).42 Thorlund and colleagues also per-
formed NMA yielding a comparable point estimate of
IFX superiority over ADA, but using informative priors
they reported statistical signiﬁcance (OR = 0.42, 95%
CrI: 0.17–0.97).43 Deciding on whether to use informa-
tive priors remains controversial. A recent report by the
Agency for Healthcare Research and Quality (AHRQ)
evaluated various studies that used mixed treatment
comparisons and concluded there is enough data to sup-
port using informative priors.44 Choosing non-informa-
tive priors for this NMA favours a lower likelihood of
type I error (false positive) at the cost of increased
type-II error (false negative); this represents the primary
bias in our approach.
In conclusion, IFX, ADA and CZP are all effective
treatments for induction and maintenance of remission
and response in Crohn’s disease. Network meta-analysis
did not demonstrate statistically signiﬁcant therapeutic
differences among anti-TNF therapies. In the absence
of compelling data demonstrating variable efﬁcacy, fac-
tors including safety, cost and patient preference should
guide anti-TNF choice and sequencing. The large sam-
ple sizes required to demonstrate differences among
anti-TNFs make these trial comparisons impractical and
unlikely to ever occur, lending value to our NMA,
though NMA may be insensitive to small differences in
clinical efﬁcacy in the absence of direct comparative
trial data to inform the network. Future therapeutic tri-
als in CD using objective quantitative measures of dis-
ease activity such as endoscopic and radiographic
scoring, may allow indirect simulation-based compari-
sons like NMA to better approximate true comparative
efﬁcacy.45, 46
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